US 11,857,001 B2
Antipathogenic face mask
Bryan J. McEntire, Salt Lake City, UT (US); Ryan M. Bock, Salt Lake City, UT (US); and Bhajanjit Singh Bal, Salt Lake City, UT (US)
Assigned to SINTX Technologies, Inc., Salt Lake City, UT (US)
Filed by SINTX TECHNOLOGIES, INC., Salt Lake City, UT (US)
Filed on Apr. 14, 2021, as Appl. No. 17/230,284.
Application 17/230,284 is a continuation in part of application No. 16/550,605, filed on Aug. 26, 2019, granted, now 11,192,787.
Claims priority of provisional application 63/009,842, filed on Apr. 14, 2020.
Claims priority of provisional application 62/727,724, filed on Sep. 6, 2018.
Claims priority of provisional application 62/800,034, filed on Feb. 1, 2019.
Prior Publication US 2021/0235791 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. D06B 13/00 (2006.01); D06M 13/00 (2006.01); A41D 13/11 (2006.01); D06M 11/77 (2006.01); D06M 101/20 (2006.01)
CPC A41D 13/1192 (2013.01) [D06B 13/00 (2013.01); D06M 11/77 (2013.01); A41D 2500/30 (2013.01); D06M 2101/20 (2013.01); D10B 2501/04 (2013.01)] 10 Claims
 
1. An antiviral face mask comprising:
a face mask body comprising:
a fibrous material layer comprising silicon nitride powder embedded in the fibrous material layer, wherein the silicon nitride is present in an inner surface of the fibrous material layer at a concentration of about 1 wt. % to about 15 wt. %; wherein the powder has an average particle size of 0.6 μm to 5 μm, and
wherein the silicon nitride inactivates a human virus in contact with the fibrous material layer of the face mask body,
wherein the virus is not SARS-CoV-2.